Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (742)	9/3/1998 8:08:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

[PFE LLY BAX] 09/03 18:43 Inhale drug system holds fans - Business Week NEW YORK, Sept 3 (Reuters) - Inhale Therapeutic Systems Inc. <INHL.O> may have seen its stock drop of late, but its fans remain bullish on the company, according to the Sept. 7 issues of Business Week. Pfizer Inc. <PFE.N>, Eli Lilly & Co. <LLY.N> and Baxter International Inc. <BAX.N> have all invested in Inhale, which makes a pulmonary device that would allow for delivery of drugs through inhalation. Pfizer has a 5 percent stake in Inhale and has conducted tests for an inhaled insulin. A third clinical trial is scheduled for November, Business Week said. Baxter spend $20 million in March 1996 to co-develop compounds for Inhale's pulmonary system. Lilly paid $10 million for an inhaled osteoporosis agent and another undisclosed compound, the magazine said. "Inhale's outstanding - but low-risk - opportunity in pulmonary delivery is undervalued by the market," Peter Ginsburg of the Minneapolis investment firm Piper-Jaffray told Business Week. Ginsburg estimates sales of drugs that can be switched to the pulmonary route could top $10 billion, the magazine said. Inhale stock closed down 3/8 at 23-1/4 on the Nasdaq Thursday. Business Week said it hit 37-1/4 last October.